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Abstract (+)-MK-801 is known to be a specific non-competitive
antagonist of N-methyl-D-aspartate (NMDA) receptors. How-
ever, besides having an anticonvulsant effect, this compound
possesses a central sympathomimetic effect and an anxiolytic-
like action, raising the possibility that (+)-MK-801 might affect
monoamine uptake systems. To elucidate this possibility, we
investigated the effects of (+)-MK-801 on monoamine transpor-
ters expressed in HEK cells. (+)-MK-801 significantly inhibited
the uptake of all three monoamine transporters in a dose-
dependent manner and the inhibitions were competitive with
respect to monoamines. The Ki values of (+)-MK-801 on the
norepinephrine, dopamine and serotonin transporters were 3.2
WM, 40 WM and 43 WM, respectively. In addition, (3)-MK-801,
a less potent antagonist of NMDA receptors, also inhibited
monoamine transporters with a similar potency as that of (+)-
MK-801. These results clearly indicate that MK-801, a non-
competitive antagonist of NMDA receptors, competitively
inhibits monoamine transporters without stereoselectivity.
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1. Introduction
(+)-MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-
cyclohepten-5,10-imine maleate) is a non-competitive N-meth-
yl-D-aspartate (NMDA) receptor antagonist binding the phen-
cyclidine (PCP) binding site of the receptors [1]. Like
phencyclidine, (+)-MK-801 is also known to possess central
sympathomimetic and psychotomimetic e¡ects as well as a
potent anticonvulsant e¡ect [2^4]. These symptoms raise the
possibility that (+)-MK-801 might a¡ect monoaminergic neu-
rotransmission. In fact, many studies have reported that
monoamine systems are potentiated after administration of
(+)-MK-801 [5^8]. Furthermore, some studies have shown
using slices or synaptosomes that (+)-MK-801 inhibits mono-
amine uptake [9^11]. These ¢ndings strongly suggest that (+)-
MK-801 inhibits transporter-mediated monoamine uptake,
leading to the potentiation of monoaminergic neurotransmis-
sion. However, the exact relationship between (+)-MK-801
and monoamine transporters has not been well delineated.
Recently, monoamine (norepinephrine, dopamine and sero-
tonin) transporters, responsible for the high-a⁄nity mono-
amine uptake systems, have been cloned [12^18]. These trans-
porters are widely expressed in monoaminergic neurons in the
central nervous system and have been shown to be of great
importance in many physiological and psychological phenom-
ena. The discovery of these genes also enabled us to directly
study the e¡ects of (+)-MK-801 on each monoamine trans-
porter. Thus, we constructed cell lines which stably express
monoamine transporters, and investigated the e¡ects of (+)-
MK-801 on them. In the present study, we show that MK-
801, a non-competitive antagonist of NMDA receptors, com-
petitively inhibits monoamine transporters without stereose-
lectivity.
2. Materials and methods
2.1. Materials
(+)-MK-801, (3)-MK-801 and 3-(( þ )-2-carboxypiperazin-4-yl)-
propyl-1-phosphonic acid (CPP) were purchased from Research Bio-
chemicals International (Massachusetts, USA). [3H]Norepinephrine,
[3H]dopamine, [3H]serotonin and [14C]glutamate with speci¢c activ-
ities of 15.0, 21.5, 24.4 and 261.6 Ci/mmol were purchased from
New England Nuclear, Boston, MA.
2.2. Construction of HEK cells stably expressing transporters
Human embryonic kidney cells (HEK 293 cells; ATCC CRL1573)
were transfected using the Chen-Okayama method with the human
norepinephrine transporter (NET), rat dopamine transporter (DAT),
rat serotonin transporter (SERT) and bovine glutamate/aspartate
transporter (GLAST) cDNAs subcloned into the eukaryotic expres-
sion vector pBK/CMV (Stratagene), which contains the gene for ge-
neticin resistance. The human norepinephrine transporter cDNA
clone (pNET) was a kind gift of Dr. Susan Amara (Oregon Health
Sciences University, USA). The rat cDNAs for the dopamine trans-
porter and serotonin transporter were cloned by Shimada and Schloss,
respectively. 24 h after the transformation, geneticin (1 mg/ml) was
added into DMEM/10% FCS and selection was done for 4 weeks.
Cells which obtained geneticin resistance were used for further experi-
ments. We designated these cells HEK-NET, HEK-DAT, HEK-
SERT and HEK-GLAST cells.
2.3. Uptake assay
For uptake measurements, HEK-NET, HEK-DAT, HEK-SERT
and HEK-GLAST cells were plated into 24-well dishes. After these
cells had reached con£uence, the culture medium was removed and
the cells were washed once with 0.2 ml transport bu¡er (TB: 125 mM
NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH
7.5). After washing, 0.2 ml TB containing [3H]norepinephrine,
[3H]dopamine, [3H]serotonin or [14C]glutamate was applied into
each well to yield ¢nal concentrations of 133.4 nM, 93.0 nM, 80.2
nM and 1.53 WM, respectively. Following incubation at room temper-
ature for 6 min, the solution was removed by suction and the cells
were washed twice with TB and then extracted with 0.4 ml of 10%
(w/v) sodium dodecyl sulfate. Radioactivity was determined by scin-
tillation counting using a Beckman LS600011C scintillation counter.
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The speci¢c [3H]monoamine and [14C]glutamate uptakes were deter-
mined as the di¡erence between the uptake values measured in HEK-
NET, DAT, SERT or GLAST and those in untransfected HEK.
Three independent experiments each in quadruplicate were performed.
Inhibition curves were ¢tted (Cricket Graph III, Computer Associates
International Inc., USA) to determine the IC50 and Hill coe⁄cient.
IC50 and Hill coe⁄cient were determined using non-linear iterative
curve ¢tting to a sigmoid function: V = 100UIh/(Ih+Ch), where V is
% control of uptake, I is the IC50 value, h is the Hill coe⁄cient, and C
is the concentration of MK-801. Then we converted IC50 values to Ki
values using the Cheng and Pruso¡ equation, Ki = IC50/(1+[L]/Km)
where [L] is the radioligand concentration of norepinephrine, dopa-
mine or serotonin. Protein concentrations were determined by the
Detergent Compatible Protein Assay (Bio-Rad), using bovine serum
albumin as a standard.
3. Results
3.1. Assessment of HEK cells expressing monoamine
transporters
To assess the ability of HEK cells expressing monoamine
transporters (HEK-NET, HEK-DAT and HEK-SERT cells)
to take up the corresponding molecules, we performed uptake
assays. After 6 min incubation with 133.4 nM
[3H]norepinephrine, 93.0 nM [3H]dopamine or 80.2 nM
[3H]serotonin, HEK-NET, HEK-DAT and HEK-SERT cells
took up 27.6 þ 1.0, 15.2 þ 0.64, and 10.2 þ 0.56 pmol/mg pro-
tein of the corresponding molecules, respectively (Fig. 1A^C).
These values were 19.7, 9.5 and 17 times higher than those of
control HEK cells respectively, showing that these three cell
lines express the corresponding functional transporters.
Uptake was linear with respect to time at least until 8 min
for each transporter (data not shown). Thus, in the following
experiments, uptake was routinely determined after 6 min at
room temperature. Competition studies with increased con-
centration of unlabeled substrate revealed that Km values
for [3H]norepinephrine, [3H]dopamine or [3H]serotonin were
about 864 nM, 1406 nM, 1170 nM, respectively.
3.2. E¡ect of (+)-MK-801 on monoamine transporters
To investigate the e¡ect of (+)-MK-801 on the norepine-
phrine transporter, we added various concentrations of (+)-
MK-801 to the uptake bu¡er (the transport bu¡er containing
133.4 nM [3H]norepinephrine) and performed inhibition as-
says using HEK-NET cells. The uptake of tracer was hardly
inhibited at 100 nM. However, above 100 nM, (+)-MK-801
signi¢cantly inhibited the uptake dose-dependently (Fig. 2A).
The IC50 value was 3.7 þ 1.2 WM, and the Hill coe⁄cient was
0.98 þ 0.02 (n = 3). To exclude the possibility that the inhibi-
tion is mediated by NMDA receptors, we performed the same
experiments with CPP, a competitive NMDA receptor antag-
onist. However, CPP did not a¡ect norepinephrine uptake
(Fig. 2A).
We also investigated using HEK-DAT cells the e¡ect of
(+)-MK-801 on the dopamine transporter. (+)-MK-801 inhib-
ited the dopamine transporter above 1 WM. At 1 mM, (+)-
MK-801 inhibited it almost completely (Fig. 2B). The IC50
value was 435.8 WM and the Hill coe⁄cient was 0.97 þ 0.02
(n = 3). In contrast, CPP did not inhibit dopamine uptake
(Fig. 2B).
(+)-MK-801 also inhibited serotonin uptake mediated by
the serotonin transporter above 1 WM (Fig. 2C). At 1 mM,
(+)-MK-801 inhibited it almost completely (Fig. 2C). The
IC50 value was 475.8 WM and the Hill coe⁄cient was
0.95 þ 0.03 (n = 3). CPP did not a¡ect serotonin uptake (Fig.
2C).
3.3. Competition experiments
To elucidate whether (+)-MK-801 inhibits monoamine
transporters competitively or non-competitively, we measured
uptake velocities under various concentrations of substrate in
the presence or absence of (+)-MK-801 for each transporter.
Lineweaver-Burk double reciprocal plot analyses showed that,
for each transporter, two lines intercepted on the vertical axis,
clearly indicating that the (+)-MK-801-induced inhibition was
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Fig. 1. Ligand uptake into HEK-NET, DAT, SERT cells and HEK cells (control). The cells were incubated with transport bu¡ers containing
133.4 nM [3H]norepinephrine, 93.0 nM [3H]dopamine or 80.2 nM [3H]serotonin. Uptake was determined after 6 min. Each point represents the
mean þ S.D. of two experiments run in quadruplicate.
Table 1
E¡ects of (+)- and (3)-MK-801 on monoamine transporters expressed in HEK cells
(+)-MK-801 (3)-MK-801
Ki (WM) Hill coe⁄cient Ki (WM) Hill coe⁄cient
NET 3.1 þ 1.1 0.98 þ 0.02 3.7 þ 3.2 0.97 þ 0.03
DAT 40 þ 5.4 0.97 þ 0.02 40 þ 5.7 0.96 þ 0.02
SERT 43 þ 5.4 0.95 þ 0.03 47 þ 8.8 0.94 þ 0.04
Each value represents the mean þ S.E.M. of three independent experiments performed in quadruplicate.
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competitive for all three monoamine transporters (Fig. 3).
Thus, we converted the IC50 values to Ki values using the
Cheng and Pruso¡ equation. Ki values of (+)-MK-801 for
the norepinephrine, dopamine and serotonin transporters
were 3.2 þ 1.1 WM, 40 þ 5.4 WM, and 43 þ 5.4 WM, respectively
(Table 1).
3.4. E¡ect of (+)-MK-801 on a glutamate transporter
To elucidate whether (+)-MK-801 speci¢cally inhibits
monoamine transporters, we investigated the e¡ects of (+)-
MK-801 on bovine glutamate/aspartate transporter (GLAST)
stably expressed in HEK cells. After 6 min incubation with
1.53 WM [14C]glutamate, HEK-GLAST cells took up
590 þ 45.1 pmol/mg protein of [14C]glutamate, and this value
was signi¢cantly higher than that of control HEK cells, which
was 163 þ 13.0 pmol/mg protein of [14C]glutamate (P6 0.01).
Competition studies with increased unlabeled substrate re-
vealed its Km value to be 70 WM. We compared the inhibitory
e¡ect of a high concentration of (+)-MK-801 on the gluta-
mate/aspartate transporter to those on monoamine transport-
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Fig. 2. E¡ects of (+)-MK-801 and CPP on the norepinephrine trans-
porter (A), dopamine transporter (B) and serotonin transporter (C).
HEK-NET, HEK-DAT or HEK-SERT cells were incubated with
transport bu¡ers containing 133.4 nM [3H]norepinephrine, 93.0 nM
[3H]dopamine or 80.2 nM [3H]serotonin and various concentrations
of MK-801 (¢lled symbols) or CPP (open diamonds). Uptake was
determined after 6 min. Each point represents the mean þ S.E.M. of
three experiments run in quadruplicate.
Fig. 3. Lineweaver-Burk plots of (+)-MK-801 inhibition on the nor-
epinephrine transporter (A), dopamine transporter (B), and seroto-
nin transporter (C). Uptake velocities (V [pmol/mg protein/min])
were measured for 6 min on various substrate concentrations (S
[WM]) in the presence (b, solid line) and the absence (a, broken
line) of (+)-MK-801 (3.2 WM in A, 40 WM in B, 43 WM in C).
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ers. 1 mM (+)-MK-801 inhibited the glutamate/aspartate
transporter only 8.2 þ 2.4%, while the same dose of (+)-MK-
801 inhibited monoamine transporters almost completely
(94.5 þ 4.4% on the norepinephrine transporter, 89.8 þ 3.6%
on the dopamine transporter, and 89.4 þ 1.4% on the seroto-
nin transporter), indicating that (+)-MK-801 preferentially in-
hibits monoamine transporters.
3.5. E¡ect of (3)-MK-801 on monoamine transporters
To elucidate whether the inhibition is stereoselective or not,
we studied the e¡ect of (3)-MK-801, a less active form of the
NMDA receptor, on monoamine transporters. Inhibition
analysis revealed that Ki values of (3)-MK-801 for norepi-
nephrine, dopamine and serotonin transporter were 3.7 þ 3.2
WM, 40 þ 5.7 WM, and 47 þ 8.8 WM, respectively (Table 1),
indicating that there was no signi¢cant di¡erence in the po-
tency of inhibiting monoamine uptake between the two opti-
cal isomers.
4. Discussion
(+)-MK-801 is widely used as a non-competitive NMDA
receptor antagonist. Besides as an anticonvulsant, it is also
known to have sympathomimetic and psychotomimetic prop-
erties [2^4]. This suggests that monoaminergic systems are
involved in the pharmacological mechanism of (+)-MK-801.
In fact, many lines of evidence indicate that monoaminergic
systems are potentiated after (+)-MK-801 administration [5^
8]. Although this potentiation has been mainly thought to be
mediated by the inhibition of the NMDA receptor itself, some
studies have shown using slices or synaptosomes that (+)-
MK-801 directly inhibits monoamine uptake [9^11]. Accord-
ing to these studies, (+)-MK-801 blocks most potently
[3H]norepinephrine uptake (IC50 about 2 WM) and
[3H]dopamine uptake with relatively low potency (IC50 about
100 WM). Our present data coincide well with these values,
supporting the possibility that the monoamine uptake systems
inhibited by (+)-MK-801 in vivo are exactly monoamine
transporters. In addition, to exclude the possibility that the
(+)-MK-801-induced inhibition is mediated by blocking
NMDA receptors expressed in HEK cells, we performed the
same experiments using CPP, a competitive NMDA receptor
antagonist. However, even 1 mM CPP showed no e¡ect on
the uptake, indicating that (+)-MK-801 directly a¡ects mono-
amine transporters.
Like PCP, (+)-MK-801 has been known to have two bind-
ing sites in the brain [19,20]. Site 1 is associated with NMDA
receptors and site 2 has been postulated to be monoamine
uptake systems. The a⁄nity of (+)-MK-801 on site 2 are
reported to be about 5^10 WM. These values coincide well
with the Ki value of the norepinephrine transporter obtained
in the present study (3.2 WM), suggesting that site 2 might be
the norepinephrine transporter. Additionally, most com-
pounds binding the PCP site of NMDA receptors such as
PCP and ketamine have been reported to bind monoamine
transporters as well [19,20]. It is, thus, intriguing to compare
the pharmacological properties of these two binding sites for
MK-801. A mutation analysis has clearly shown that the
binding site for MK-801 on NMDA receptor subunit 1 re-
quires an interplay of residues from its transmembrane 2 and
3 segments, which are situated in the center of the ionic pore
[21]. In addition, the authors have speculated that hydrogen
bonding between asparagine at position 582 and imine (-NH)
on MK-801 is important for the binding. Furthermore, Lee-
son et al. reported that the MK-801 recognition site on the
NMDA receptor ion channel requires size-limited hydropho-
bic binding of both aromatic rings, and strictly directional
hydrogen bond donation from protonated quaternary nitro-
gen atom [22]. These ¢ndings suggest that the binding site of
the NMDA receptor for MK-801 is highly selective. In fact,
the site shows strict stereoselectivity for MK-801 [1]. Wong et
al. have reported that (3)-MK-801 is one-seventh as potent as
(+)-MK-801. In contrast, as we present in this study, the bind-
ing sites on monoamine transporters show no stereoselectivity
for MK-801. The monoamines, substrates of monoamine
transporters, share structural similarity with one of the aro-
matic rings and the nitrogen atom of MK-801. Thus, we spec-
ulate that MK-801 would bind monoamine transporters only
with one of the benzene rings and the imine residue, causing
the relatively weak a⁄nity for monoamine transporters.
Since MK-801 is a ‘non-competitive’ antagonist of NMDA
receptors, its binding site and the glutamate binding site on
the receptor complex are completely di¡erent. On the other
hand, we found that the inhibitory e¡ects of MK-801 for
monoamine transporters are competitive with respect to
monoamines, indicating that the MK-801 binding sites on
monoamine transporters overlap the monoamine binding sites
on them. It might be of interest to ¢nd where these sites are
located in each protein, and to investigate the structural rela-
tionship among them.
(+)-MK-801 is normally used at doses of 0.1^0.5 mg/kg
when intraperitoneally injected into rats [9^11]. Vezzani et
al. reported that these doses give maximal concentrations of
about 0.2^1.0 WM in the brain [23]. These concentrations seem
enough to a¡ect at least the norepinephrine transporter, be-
cause (+)-MK-801 gives almost 30% inhibition at 1 WM (Fig.
2A). In addition, if the concentration of (+)-MK-801 in the
synaptic cleft is higher than this estimation, it might be pos-
sible that the dopamine and serotonin transporters are also
a¡ected. Thus, when (+)-MK-801 is used as a speci¢c antag-
onist of the NMDA receptor, the possibility that (+)-MK-801
also a¡ects monoamine transporters should be cautiously con-
sidered.
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